亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Subcutaneous Infliximab, CT-P13 SC: A Profile of Its Use in the EU

医学 英夫利昔单抗 生物仿制药 溃疡性结肠炎 银屑病性关节炎 强直性脊柱炎 类风湿性关节炎 银屑病 炎症性肠病 内科学 疾病 皮肤病科 胃肠病学
作者
Matt Shirley
出处
期刊:Clinical Drug Investigation [Adis, Springer Healthcare]
卷期号:41 (12): 1099-1107 被引量:4
标识
DOI:10.1007/s40261-021-01093-8
摘要

CT-P13 (Remsima®; Inflectra®), a biosimilar of reference infliximab (Remicade®), provides a useful alternative for patients requiring infliximab therapy and, as with other biosimilar agents, has the potential to reduce treatment costs. Furthermore, the availability of CT-P13 in a subcutaneous formulation (CT-P13 SC), with the possibility (after adequate training) of self-administration at home, has the potential to both improve patient convenience and reduce the burden on the healthcare system. The initial approval of CT-P13 SC, for use in the treatment of rheumatoid arthritis in adults, was based on the findings of a randomised, double-blind phase I/III trial which demonstrated the non-inferiority of CT-P13 SC administered once every 2 weeks to intravenous CT-P13 (CT-P13 IV) administered once every 8 weeks in reducing disease activity in patients with active rheumatoid arthritis. Subsequently, based on pharmacokinetic data in patients with inflammatory bowel disease, CT-P13 SC has also been approved in the EU for use in the treatment of Crohn's disease, ulcerative colitis and, by extrapolation, ankylosing spondylitis, psoriatic arthritis and psoriasis, in adults.Biosimilars are biological medical agents that are designed to closely replicate a reference medicine while potentially reducing treatment costs. CT-P13 (Remsima®; Inflectra®) in the intravenous formulation (CT-P13 IV) is a biosimilar of reference infliximab (Remicade®) and is approved in the EU for use in the treatment of rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriatic arthritis and psoriasis in adults and Crohn’s disease and ulcerative colitis in children aged ≥ 6 years. Unlike reference infliximab, CT-P13 is now also available in a formulation that can be administered by subcutaneous injection (CT-P13 SC). CT-P13 SC is approved for use in adults (only) in all indications as for CT-P13 IV, with approval based on clinical trials which showed that the subcutaneous formulation has non-inferior efficacy to CT-P13 IV in the treatment of rheumatoid arthritis and has non-inferior pharmacokinetics to the intravenous formulation in patients with inflammatory bowel disease. In conclusion, CT-P13 SC provides a useful alternative for adult patients requiring infliximab therapy and, with the possibility of self-administration at home, has the potential both to improve patient convenience and to reduce the burden on the healthcare system.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
reerwt完成签到,获得积分20
4秒前
19秒前
陈元元K完成签到,获得积分10
25秒前
英俊的铭应助科研通管家采纳,获得10
29秒前
小二郎应助科研通管家采纳,获得10
29秒前
33秒前
梦梦发布了新的文献求助10
38秒前
42秒前
caca完成签到,获得积分0
43秒前
科研通AI2S应助YYYCCCCC采纳,获得10
1分钟前
海鸥别叫了完成签到 ,获得积分10
2分钟前
云霞完成签到 ,获得积分10
2分钟前
朴素的山蝶完成签到 ,获得积分10
2分钟前
2分钟前
FashionBoy应助科研通管家采纳,获得10
2分钟前
Bugs完成签到,获得积分10
2分钟前
2分钟前
小八统治世界完成签到 ,获得积分10
2分钟前
tang完成签到,获得积分10
3分钟前
汉堡包应助舒服的觅夏采纳,获得10
3分钟前
suicone完成签到,获得积分10
3分钟前
zqq完成签到,获得积分0
3分钟前
3分钟前
归陌完成签到 ,获得积分10
3分钟前
3分钟前
mmyhn发布了新的文献求助10
3分钟前
4分钟前
Dave发布了新的文献求助10
4分钟前
4分钟前
科研通AI2S应助科研通管家采纳,获得10
4分钟前
4分钟前
wbs13521完成签到,获得积分0
5分钟前
5分钟前
儒雅致远发布了新的文献求助10
5分钟前
5分钟前
Hello应助儒雅致远采纳,获得10
5分钟前
正在获取昵称中...完成签到,获得积分10
5分钟前
5分钟前
爆米花应助xiongdi521采纳,获得10
6分钟前
6分钟前
高分求助中
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3990045
求助须知:如何正确求助?哪些是违规求助? 3532108
关于积分的说明 11256354
捐赠科研通 3270943
什么是DOI,文献DOI怎么找? 1805146
邀请新用户注册赠送积分活动 882270
科研通“疑难数据库(出版商)”最低求助积分说明 809228